The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency ...

The drug, which functions similar to psilocybin, scored positive enough results in a mid-stage study that Reunion is now ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

The oncology patent cliff presents a complex and urgent challenge. As blockbuster therapies approach loss of exclusivity, the ...

A new wave of Alzheimer’s research suggests semaglutide, widely known for diabetes and weight loss, could also slow cognitive ...

Pfizer has agreed to buy Seattle-based Seagen for $43 billion in a blockbuster deal that would unite the pharmaceutical giant with a biotechnology company that pioneered a new type of tumor-killing ...

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...